Innate Immunity Fights Alzheimer's Disease

Trends in Neurosciences

Volumn 38, Issue 11, 2015, Pages 674-681

  Guillot Sestier, Marie Victoire ^a   Doty, Kevin R ^a   Town, Terrence ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Amyloid; Apolipoprotein E; Immunotherapy; Interleukin 10; Microglia; Phagocytosis

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; INTERLEUKIN 10; STAT3 PROTEIN; CYTOKINE;

ALZHEIMER DISEASE; AMYLOIDOSIS; ASTROCYTE; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; GENETIC RISK; GLIA CELL; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; MENINGITIS; MICROGLIA; MONOCYTE; MONONUCLEAR PHAGOCYTE; MOUSE MODEL; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PHAGOCYTOSIS; PHAGOLYSOSOME; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BRAIN; DISEASE MODEL; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, INNATE; MICE; MICROGLIA;

EID: 84947781432     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2015.08.008     Document Type: Review

References (69)

1. Brookmeyer R., et al. National estimates of the prevalence of Alzheimer's disease in the United States. Alzheimers Dement. 2011, 7:61-73.
2. Heneka M.T., et al. Innate immunity in Alzheimer's disease. Nat. Immunol. 2015, 16:229-236.
3. Yan R., Vassar R. Targeting the β secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol. 2014, 13:319-329.
4. Golde T.E., et al. γ-Secretase inhibitors and modulators. Biochim. Biophys. Acta 2013, 1828:2898-2907.
5. Mawuenyega K.G., et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010, 330:1774.
6. Hickman S.E., et al. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J. Neurosci. 2008, 28:8354-8360.
7. Johnston H., et al. Assessing the contribution of inflammation in models of Alzheimer's disease. Biochem. Soc. Trans. 2011, 39:886-890.
8. Orre M., et al. Isolation of glia from Alzheimer's mice reveals inflammation and dysfunction. Neurobiology 2014, 35:2746-2760.
9. Heneka M.T., et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015, 14:388-405.
10. Town T., et al. The microglial 'activation' continuum: from innate to adaptive responses. J. Neuroinflamm. 2005, 2:24.
11. Gjoneska E., et al. Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer's disease. Nature 2015, 518:365-369.
12. Reitz C., Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem. Pharmacol. 2014, 88:640-651.
13. Hazrati L-N., et al. Genetic association of CR1 with Alzheimer's disease: a tentative disease mechanism. Neurobiol. Aging 2012, 33. 2949.e5-2949.e12.
14. Griciuc A., et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 2013, 78:631-643.
15. Hardy J., et al. Pathways to Alzheimer's disease. J. Intern. Med. 2014, 275:296-303.
16. Jaturapatporn D., et al. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst. Rev. 2012, 2:CD006378.
17. Szekely C.A., Zandi P.P. Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence. CNS Neurol. Disord. Drug Targets 2010, 9:132-139.
18. Breitner J.C., et al. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement. 2011, 7:402-411.
19. Leoutsakos J-M.S., et al. Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial. Int. J. Geriatr. Psychiatry 2012, 27:364-374.
20. Heneka M.T., et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 2013, 493:674-678.
21. Fuhrmann M., et al. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat. Neurosci. 2010, 13:411-413.
22. Berg, vom J., et al. Inhibition of IL12/IL23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat. Med. 2012, 18:1812-1819.
23. Lee S., et al. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. Am. J. Pathol. 2010, 177:2549-2562.
24. Lee S., et al. Opposing effects of membrane-anchored CX3CL1 on amyloid and tau pathologies via the p38 MAPK pathway. J. Neurosci. 2014, 34:12538-12546.
25. Gezen-Ak D., et al. BDNF, TNFα, HSP90, CFH, and IL-10 serum levels in patients with early or late onset Alzheimer's disease or mild cognitive impairment. J. Alzheimers Dis. 2013, 37:185-195.
26. Akiyama H., et al. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21:383-421.
27. Weeraratna A.T., et al. Alterations in immunological and neurological gene expression patterns in Alzheimer's disease tissues. Exp. Cell Res. 2007, 313:450-461.
28. Wyss-Coray T., et al. Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease. Nature 1997, 389:603-606.
29. Vural P., et al. The combinations of TNFalpha-308 and IL-6-174 or IL-10-1082 genes polymorphisms suggest an association with susceptibility to sporadic late-onset Alzheimer's disease. Acta Neurol. Scand. 2009, 120:396-401.
30. Arosio B., et al. Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer's disease. Neurobiol. Aging 2004, 25:1009-1015.
31. Lio D., et al. Interleukin-10 promoter polymorphism in sporadic Alzheimer's disease. Genes Immun. 2003, 4:234-238.
32. Ma S.L., et al. The association between promoter polymorphism of the interleukin-10 gene and Alzheimer's disease. Neurobiol. Aging 2005, 26:1005-1010.
33. Depboylu C., et al. Lack of association of interleukin-10 promoter region polymorphisms with Alzheimer's disease. Neurosci. Lett. 2003, 342:132-134.
34. Ramos E.M., et al. Tumor necrosis factor alpha and interleukin 10 promoter region polymorphisms and risk of late-onset Alzheimer disease. Arch. Neurol. 2006, 63:1165-1169.
35. Scassellati C., et al. Promoter haplotypes of interleukin-10 gene and sporadic Alzheimer's disease. Neurosci. Lett. 2004, 356:119-122.
36. Strle K., et al. Interleukin-10 in the brain. Crit. Rev. Immunol. 2001, 21:427-449.
37. Guillot-Sestier M-V., et al. Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neuron 2015, 85:534-548.
38. Zhang B., et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell 2013, 153:707-720.
39. Li X., et al. Integrated genomic approaches identify major pathways and upstream regulators in late onset Alzheimer's disease. Sci. Rep. 2015, 5:12393.
40. Town T., et al. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat. Med. 2008, 14:681-687.
41. Gate D., et al. Macrophages in Alzheimer's disease: the blood-borne identity. J. Neural Transm. 2010, 117:961-970.
42. Rezai-Zadeh K., et al. How to get from here to there: macrophage recruitment in Alzheimer's disease. Curr. Alzheimer Res. 2011, 8:156-163.
43. Chakrabarty P., et al. IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron 2015, 85:519-533.
44. Williams L.M., et al. Interleukin-10 suppression of myeloid cell activation - a continuing puzzle. Immunology 2004, 113:281-292.
45. Murray P.J. Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. Curr. Opin. Pharmacol. 2006, 6:379-386.
46. Banchereau J., et al. From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat. Immunol. 2012, 13:925-931.
47. Doty K.R., et al. The role of the immune system in neurodegenerative disorders: Adaptive or maladaptive?. Brain Res. 2014, 1617:155-173.
48. Loewenbrueck K.F., et al. Th1 responses to beta-amyloid in young humans convert to regulatory IL-10 responses in Down syndrome and Alzheimer's disease. Neurobiol. Aging 2010, 31:1732-1742.
49. Holness C.L., Simmons D.L. Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood 1993, 81:1607-1613.
50. Guillot-Sestier M-V., Town T. Innate immunity in Alzheimer's disease: a complex affair. CNS Neurol. Disord. Drug Targets 2013, 12:593-607.
51. Rezai-Zadeh K., et al. CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease?. J. Neuroimm. Pharmacol. 2009, 4:462-475.
52. Weitz T.M., Town T. Microglia in Alzheimer's disease: it's all about context. Int. J. Alzheimers Dis. 2012, 2012:314185.
53. Lee D.C., et al. Review: experimental manipulations of microglia in mouse models of Alzheimer's pathology: activation reduces amyloid but hastens tau pathology. Neuropathol. Appl. Neurobiol. 2013, 39:69-85.
54. Kanekiyo T., et al. ApoE and Aβ in Alzheimer's disease: accidental encounters or partners?. Neuron 2014, 81:740-754.
55. Tai L.M., et al. Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. J. Biol. Chem. 2013, 288:5914-5926.
56. Paris D., et al. Isoform-specific vasoconstriction induced by apolipoprotein E and modulation of this effect by Alzheimer's beta-amyloid peptide. Neurosci. Lett. 1998, 256:73-76.
57. Rodriguez G.A., et al. Human APOE4 increases microglia reactivity at Aβ plaques in a mouse model of Aβ deposition. J. Neuroinflamm. 2014, 11:111.
58. Hudry E., et al. Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci. Transl. Med. 2013, 5:212ra161.
59. Hashimoto T., et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide. J. Neurosci. 2012, 32:15181-15192.
60. Garai K., et al. The binding of apolipoprotein E to oligomers and fibrils of amyloid-β alters the kinetics of amyloid aggregation. Biochemistry 2014, 53:6323-6331.
61. Cerf E., et al. High ability of apolipoprotein E4 to stabilize amyloid-β peptide oligomers, the pathological entities responsible for Alzheimer's disease. FASEB J. 2011, 25:1585-1595.
62. Pankiewicz J.E., et al. Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE e2 and e4 targeted replacement Alzheimer model mice. Acta Neuropathol. Commun. 2014, 2:75.
63. Mulder S.D., et al. Apolipoproteins E and J interfere with amyloid-beta uptake by primary human astrocytes and microglia in vitro. Glia 2014, 62:493-503.
64. Yu J-T., et al. Apolipoprotein E in Alzheimer's disease: an update. Annu. Rev. Neurosci. 2014, 37:79-100.
65. Ni G., et al. Manipulating IL-10 signalling blockade for better immunotherapy. Cell. Immunol. 2015, 293:126-129.
66. Munoz J., et al. STAT3 inhibitors: finding a home in lymphoma and leukemia. Oncologist 2014, 19:536-544.
67. Simard A.R., et al. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 2006, 49:489-502.
68. Simard A.R., Rivest S. Neuroprotective properties of the innate immune system and bone marrow stem cells in Alzheimer's disease. Mol. Psychiatry 2006, 11:327-335.
69. Kwilasz A.J., et al. The therapeutic potential of interleukin-10 in neuroimmune diseases. Neuropharmacology 2014, 96:55-69.